Key Metrics
CiteScore 

44.4
Eigenfactor 

0.05 - 0.1
Impact Factor 

>= 25
Scite Index 

0.85 5-Year SI

SJR 

Q1Oncology

SNIP 

7.17
Recommended pre-submission checks
Powered by 

Topics Covered on JAMA Oncology
JAMA Oncology Journal Specifications
Indexed in the following public directories
Web of Science
SJR
| Overview | |
| Publisher | AMER MEDICAL ASSOC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2015 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in JAMA Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in JAMA Oncology
Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults
- 7 May 2026
- JAMA Oncology
Clarification for Gleason Pattern
- 7 May 2026
- JAMA Oncology
Reassessing Treatment Outcomes Following Immune-Related Adverse Events
- 7 May 2026
- JAMA Oncology
Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer
- 7 May 2026
- JAMA Oncology
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply
- 7 May 2026
- JAMA Oncology
Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors
- 7 May 2026
- JAMA Oncology
Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults
- 7 May 2026
- JAMA Oncology
Clarification for Gleason Pattern
- 7 May 2026
- JAMA Oncology
Reassessing Treatment Outcomes Following Immune-Related Adverse Events
- 7 May 2026
- JAMA Oncology
Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer
- 7 May 2026
- JAMA Oncology
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply
- 7 May 2026
- JAMA Oncology
Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors
- 7 May 2026
- JAMA Oncology